SCHEDULE: Affinity Funds Amend iBio Stake to 9.99% via Warrants

Affinity Asset Advisors and Affinity Healthcare Fund have amended their Schedule 13G filing, disclosing a 9.99% beneficial ownership in iBio, Inc. common stock, primarily through warrants.

Summary

• Affinity Asset Advisors, LLC and Affinity Healthcare Fund, LP have filed an Amendment No. 1 to their Schedule 13G for iBio, Inc.
• The filing corrects the number of shares beneficially owned by the reporting persons, giving effect to a 9.99% Beneficial Ownership Limitation.
• Affinity Asset Advisors, LLC acts as the investment manager for Affinity Healthcare Fund, LP and exercises investment discretion.
• As of August 26, 2025, the Fund beneficially owned 2,181,420 shares of iBio Common Stock, issuable upon exercise of warrants within 60 days, representing 9.99% of 21,836,045 outstanding shares.
• As of December 3, 2025 (the filing date), the Fund beneficially owned an aggregate of 2,495,813 shares of iBio Common Stock, issuable upon exercise of warrants within 60 days, also representing 9.99% of 24,983,121 outstanding shares.
• The beneficial ownership is capped at 9.99% due to a Beneficial Ownership Limitation clause related to the warrants.

Sentiment

Score: 7

Explanation: The filing indicates a significant and maintained institutional stake in iBio, Inc., which can be viewed positively as a sign of investor confidence. The amendment clarifies the ownership structure and adherence to a beneficial ownership limitation, providing transparency without suggesting negative operational news.

Positives

• A significant institutional investor, Affinity Healthcare Fund, maintains a substantial 9.99% stake in iBio, Inc., indicating continued confidence.
• The beneficial ownership is primarily through warrants, suggesting a long-term interest in the company's potential growth.

Negatives

• The beneficial ownership is subject to a 9.99% limitation, which caps the fund's ability to increase its percentage ownership beyond this threshold, potentially limiting future upside from increased stake.

Risks

• The beneficial ownership is derived from warrants, meaning the actual shares are not yet outstanding and their exercise is subject to the terms of the warrants and the Beneficial Ownership Limitation.
• The value of the beneficial ownership is tied to the performance of iBio's common stock, which carries inherent market risks.

Industry Context

This filing reflects an institutional investor's continued significant stake in iBio, Inc., a company operating in the biotechnology sector. Such disclosures are common for funds that reach or amend their holdings above certain thresholds, providing transparency on major shareholder positions. The consistent 9.99% ownership, despite an increase in the absolute number of shares, indicates adherence to a beneficial ownership limitation, which is a common practice in certain investment agreements to avoid triggering specific regulatory or corporate control provisions.

Stakeholder Impact

• Shareholders: The disclosure of a significant institutional stake by Affinity Healthcare Fund may instill confidence among existing shareholders and potentially attract new investors, signaling institutional belief in iBio's prospects.
• Management: Awareness of a large, stable institutional investor can influence management's strategic decisions and communication, as they are accountable to significant stakeholders.

Key Dates

Recommendation

This Schedule 13G amendment primarily provides an update on an institutional investor's beneficial ownership stake in iBio, Inc. While the maintenance of a significant 9.99% stake by Affinity Healthcare Fund can be seen as a positive signal of confidence, the filing itself does not contain operational or financial performance data that would warrant a 'buy' or 'sell' recommendation. It's a disclosure of ownership, not a fundamental analysis of the company's business. Therefore, a 'hold' recommendation is appropriate, as it suggests no immediate action based solely on this ownership update, but encourages investors to consider this information in conjunction with other financial and operational reports.

Keywords

iBio Inc, Affinity Asset Advisors, Affinity Healthcare Fund, Schedule 13G, Beneficial Ownership, Common Stock, Warrants, Institutional Investor, SEC Filing, Biotechnology, Healthcare Investment